TransThera and Akeso Biopharma Collaborate on HCC Study with Tinengotinib and Bispecific Antibodies
Chinese companies TransThera Sciences (Nanjing) Inc. and Akeso Biopharma (HKG: 9926) have formed a strategic...
NMPA Approves Qingfeng’s Suraxavir Marboxil for Influenza A and B Treatment
China’s National Medical Products Administration (NMPA) has approved suraxavir marboxil, a Category 1 drug developed...
Medtronic Launches Digital Innovation Base in Beijing’s BioPark
US-Irish firm Medtronic (NYSE: MDT) has inaugurated its digital medical innovation base at the BioPark...
Huadong Medicine Gains NMPA Approval for HDM3019 Rheumatoid Arthritis Trial
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced receiving approval from the National Medical Products...
Lee’s Pharmaceutical Holdings Ltd Reports 32.9% Revenue Growth in 2023
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) released its 2023 financial report, recording HKD 1.4...
RemeGen’s 2024 Revenue Soars 58.54% on Strong Product Sales and R&D Growth
China-based biotech RemeGen Co., Ltd (HKG: 9995, SHA: 688331) released its 2024 financial report, recording...
JW Therapeutics Sees 9% Revenue Decline in 2024 Amid Commercial Strategy Shift
China-based JW Therapeutics (HKG: 2126) released its 2024 financial report, recording RMB 158.2 million (USD...
Ascentage Pharma’s Revenue Soars 342% in 2024 on Strong Drug Sales and Partnerships
China-based Ascentage Pharma Group International (NASDAQ: AAPG, HKG: 6855) unveiled its 2024 financials, showing revenues...
Shanghai Pharmaceuticals Reports 5.75% Revenue Growth in 2024 with Innovation Initiatives
China’s Shanghai Pharmaceuticals (SPH; SHA: 601607, HKG: 2607) released its 2024 financial results, showing total...
YiChang HEC’s Yiqibuvir Approved by NMPA for Chronic HCV Infection
China-based YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG: 1558) announced receiving marketing approval from the...
Luye Pharma’s Shandong Boan Bio Reports 17.5% Revenue Growth in 2024
China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary Shandong Boan Biotechnology Co., Ltd (HKG: 6955)...
MicroPort CardioFlow Medtech Reports 7.5% Revenue Growth in 2024 Driven by Global Expansion
China-based MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160) announced its 2024 financial report, recording RMB362...
Hengrui Pharmaceuticals Gets NMPA Green Light for HRS-1738 and HRS-5817 Clinical Trials
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced receiving approval from the National Medical Products...
MicroPort MedBot Reports Strong 2024 Growth for Toumai and SkyWalker Robots
Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) revealed its 2024 financial performance, recording RMB257...
Sanofi’s mRNA Chlamydia Vaccine Gains FDA Fast Track Designation
French pharmaceutical giant Sanofi (EPA: SAN, NASDAQ: SNY) has announced receiving fast track designation from...
Fangzhou Inc. Partners with Tencent Health to Advance AI-Driven Healthcare Solutions
Guangzhou-based smart healthcare service platform Fangzhou Inc. (HKG: 6086) has announced a strategic partnership with...
Merck, Sharp & Dohme’s Capvaxive Approved by European Commission for Pneumococcal Prevention
US-based Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has announced the European Commission (EC)...
Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for SHR-9803 and SHR-A2102 Clinical Trials
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving separate clinical trial approvals from...
Servier and Black Diamond Therapeutics Ink Global Deal for Solid Tumor Targeted Therapy BDTX-4933
French pharmaceutical firm Servier has announced a global licensing agreement with US-based Black Diamond Therapeutics...
Bio-Thera Solutions Inks Licensing Deal with Dr. Reddy’s for Biosimilar Commercialization
Guangzhou-based Bio-Thera Solutions (SHA: 688177) has entered into a licensing agreement with India-headquartered Dr. Reddy’s...